Roche gains FDA approval for new breast cancer drug Wilserdly in the US

  • Share
Roche gains FDA approval for new breast cancer drug Wilserdly in the US

Swiss pharmaceutical company Roche has received approval from the US Food and Drug Administration (FDA) for its new drug Wilserdly, scientifically known as giredestrant, which will be used to treat hormone-resistant breast cancer. The drug is available in tablet form and will be administered in combination with everolimus. The FDA decision was announced on November 16, 2026, marking a significant step in the fight against advanced breast cancer.

The treatment has been approved for patients with estrogen receptor-positive (ER), HER2-negative breast cancer and the ESR1 mutation. It is intended for cases where the disease is locally advanced or metastatic and has returned or progressed following previous hormonal therapies.

One of the key advantages of this drug is its practicality: both medications are taken orally, allowing patients to continue their treatment at home without the need for injections. According to swissinfo.ch, this treatment can ease the lives of patients during the healing process.

Promising results from clinical studies

The phase three clinical study, evERA, has shown promising results. The combination of Wilserdly with everolimus reduced the risk of disease progression or death by 62%, compared to standard hormonal therapy with everolimus. Patients receiving the new treatment achieved a median time without disease progression of 10 months, while the group with traditional therapy had 5.5 months. However, authorities have emphasized that it is still unclear whether the new treatment extends overall patient survival.

Levi Garraway, Roche’s Chief Medical Officer, stated that resistance to hormonal therapies is one of the major challenges in treating advanced breast cancer. According to him, Wilserdly offers a targeted alternative that can delay disease progression and improve patients’ quality of life during therapy.

Pricing and economic potential

Roche has stated that the list price for Wilserdly in the US will be $22,500 per month. However, the company has noted that this amount does not represent the full cost for patients, as it may vary depending on health insurance, discounts, or financial assistance programs.

Analysts estimate that the treatment could contribute $500–600 million to the company’s revenues in 2027. In the long term, Urban Fritsche of the Cantonale Bank of Zurich forecasts that annual sales could reach up to 14 billion Swiss francs at their peak, around 2033. These are projections, not guaranteed revenues.

Breast cancer: a global challenge

Breast cancer is one of the most common oncological diseases worldwide. According to the World Health Organization (WHO), around 2.3 million women are diagnosed with the disease each year, while 670,000 lose their lives. Around 70% of cases are linked to hormonal receptors, making the development of new therapies a top priority in medical research.

Roche is also seeking FDA approval for Wilserdly to treat early-stage breast cancer with an average or high risk of recurrence. The FDA is expected to make a decision on this use by November 30, 2026. The US approval is a crucial step for Roche, which has been committed to developing cancer treatments for over three decades.

Finally, it is important to note that the treatment requires specialized medical evaluation, as it is not suitable for all forms of breast cancer and comes with warnings about side effects, such as slowed heart rate or fetal damage during pregnancy.

In brief

FDA approval of Wilserdly represents a major milestone in the treatment of hormone-resistant breast cancer. The combination of oral tablets with everolimus shows promising results, reducing the risk of disease progression by 62%. However, the high cost and need for medical assessment will be key factors in its adoption.

Notable individuals


Source of the news: albinfo.ch
Note: This material has been prepared for informational purposes by Portali Kosova.Today.


2 views 2 sot